Cost-Effectiveness Analysis of Adjuvant Treatment for Resected Pancreatic Cancer in China Based on the ESPAC-4 Trial

The effectiveness of gemcitabine plus capecitabine compared with gemcitabine monotherapy for resected pancreatic cancer has been evaluated in the ESPAC-4 trial.

We aimed to assess the cost-effectiveness of these adjuvant regimens on resected pancreatic cancer. Read more . . .

Join our community Sign up for updates from Let’s Win!

Terms & Conditions • Privacy Policy

Let’s Win! Pancreatic Cancer is an online community for sharing information about innovative, science-based treatments for pancreatic cancer. Please note that this information is not intended to be a substitute for professional medical opinion, advice, or diagnosis. We encourage you to use this information to begin a dialogue with your physician about the treatment plan that is right for you.